Evidence map›Paper›PMID 40777630›Full record

ArticleBiomedical reports2025

Impact of weight loss and lifestyle modifications on liver fibrosis in MASLD and MetALD: A cohort study.

Tatsuki Ichikawa, Satoshi Miuma, Mio Yamashima, Shinobu Yamamichi, Makiko Koike, Yusuke Nakano, Hiroyuki Yajima, Osamu Miyazaki, Tomonari Ikeda, Takuma Okamura and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tatsuki IchikawaDepartment of Gastroenterology, Nagasaki Harbor Medical Center, Nagasaki 850-8555, Japan.
Satoshi MiumaDepartment of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan.
Mio YamashimaDepartment of Gastroenterology, Nagasaki Harbor Medical Center, Nagasaki 850-8555, Japan.
Shinobu YamamichiDepartment of Gastroenterology, Nagasaki Harbor Medical Center, Nagasaki 850-8555, Japan.
Makiko KoikeInnovation and Translational Research Center, Nagasaki Harbor Medical Center, Nagasaki 850-8555, Japan.
Yusuke NakanoInnovation and Translational Research Center, Nagasaki Harbor Medical Center, Nagasaki 850-8555, Japan.
Hiroyuki YajimaDepartment of Gastroenterology, Nagasaki Harbor Medical Center, Nagasaki 850-8555, Japan.
Osamu MiyazakiDepartment of Gastroenterology, Nagasaki Harbor Medical Center, Nagasaki 850-8555, Japan.
Tomonari IkedaDepartment of Gastroenterology, Nagasaki Harbor Medical Center, Nagasaki 850-8555, Japan.
Takuma OkamuraDepartment of Gastroenterology, Nagasaki Harbor Medical Center, Nagasaki 850-8555, Japan.
Naohiro KomatsuDepartment of Gastroenterology, Nagasaki Harbor Medical Center, Nagasaki 850-8555, Japan.
Miruki YoshinoDepartment of Gastroenterology, Nagasaki Harbor Medical Center, Nagasaki 850-8555, Japan.
Hisamitsu MiyaakiDepartment of Gastroenterology and Hepatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to investigate the impact of weight loss and abstinence and exercise on liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatotic liver disease and alcoholic-related liver disease (MetALD). A total of 67 patients with MASLD and 33 patients with MetALD were retrospectively evaluated after six months of follow-up for weight loss, abstinence and exercise. A decrease in liver fibrosis (decrease in dLSM2B) was defined as a reduction in liver stiffness (LS) by FibroScan and macrophage galactose-specific lectin-2 binding protein glycosylation isomer (M2BPGi) over the observation period. The decrease in dLSM2B levels was 35.8 and 39.4% in the MASLD and MetALD groups, respectively. In MASLD, the decreased weight rate (dBW%) was lower for a decrease in dLSM2B than for an increase. However, in MetALD, the dBW% was not significantly different between the groups. In MetALD, patients with complete abstinence and exercise frequency had a higher rate of decrease in dLSM2B. A prediction score of 0, 1 or 2 points was developed to predict the decrease in dLSM2B, with 1 point awarded for a dBW% reduction of ≥3.8 and 1 point for a FIB-4 reduction of ≥0.201. In patients with MASLD, there was a significant difference in the decrease in dLSM2B by 8.3% for a prediction score of 0, 36% for 1, and 72.2% for 2 points, whereas there was no significant difference in the improvement rate for 0-2 points. In conclusion, weight loss during MASLD and abstinence and exercise during MetALD were associated with a decrease in dLSM2B.

Indexed as

abstinenceexerciseMASLDMetALDweight loss

Identifiers

PMID40777630
PMCPMC12329720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.